Researchers are making remarkable progress in creating a revolutionary medication that has the potential to facilitate the regrowth of teeth.
The clinical trials for this drug are set to begin in July of next year, and the goal is to make it available for dental professionals to use by the year 2030.
Although tooth defects at birth are prevalent among humans and affect approximately one percent of the global population, the development of a drug to promote the regrowth of teeth would be an unprecedented achievement.
Since the early 1990s, Dr. Katsu Takahashi, who currently serves as the head of the dentistry and oral surgery department at the Medical Research Institute Kitano Hospital, has been involved in the development of the drug.
“The idea of growing new teeth is every dentist’s dream,”
In an interview with The Mainichi, Dr. Katsu Takahashi expressed that the prospect of creating new teeth is a long-standing aspiration of every dentist. He also stated that he is optimistic about his ability to “to make it happen.”
The innovative dental project, which has received backing from the Japan Agency for Medical Research and Development (AMED), a statement on the clinic’s website.strives.
“to deliver a therapeutic drug to patients with congenital edentulism [people wholly or partially toothless] through the cooperation of more than 10 medical institutions and research institutes nationwide,”
“We believe that this research will clarify the mechanism of the disease (congenital Anodontia) for you and many other patients and contribute to the development of a cure.”
By focusing on a gene called USAG-1, which has been found to restrict tooth growth in mice, the research team has been able to promote the development of “third-generation” teeth in animal models. These teeth come after baby teeth and permanent adult teeth. The team has already accomplished this feat in their experiments.
The team of researchers has managed to induce the growth of “third-generation” teeth in animal models, which come after both baby teeth and permanent adult teeth. They accomplished this by focusing on a gene called USAG-1, which restricts tooth growth in mice.
Dr. Takahashi’s team was able to stimulate tooth regrowth in mice and ferrets by creating a neutralizing antibody medication that obstructs the function of USAG-1.
The results of the research, which were published in the scientific journal Nature in 2021, have created a buzz in the global scientific community. A drug that promotes tooth regrowth would be a groundbreaking development, providing an alternative solution for people who have lost their teeth due to severe cavities or dental diseases. Currently, efforts are underway to prepare the drug for human use. Once the safety and effectiveness of the drug are established, the focus will shift to treating children aged 2 to 6 who exhibit signs of anodontia, according to a report by The Mainichi. Dr. Takahashi anticipates a future where tooth-regrowth medication is a viable third option alongside dentures and implants, offering individuals the opportunity to restore their natural teeth.
The results of the research, which were published in the scientific journal Nature in 2021, have created a buzz in the global scientific community.
A drug that promotes tooth regrowth would be a groundbreaking development, providing an alternative solution for people who have lost their teeth due to severe cavities or dental diseases. Currently, efforts are underway to prepare the drug for human use.
Once the safety and effectiveness of the drug are established, the focus will shift to treating children aged 2 to 6 who exhibit signs of anodontia, according to a report by The Mainichi.
“We hope to pave the way for the medicine’s clinical use,“ Takahashi noted.
Dr. Takahashi anticipates a future where tooth-regrowth medication is a viable third option alongside dentures and implants, offering individuals the opportunity to restore their natural teeth.
.
